Merck KGaA, Sysmex Inostics Nab CE Mark for Colorectal Cancer Test

Merck KGaA and Sysmex Inostics’ jointly developed liquid biopsy OncoBEAM RAS CRC assay has garnered CE marking.

Comparable to tissue-based testing, the test can identify which patients with metastatic colorectal cancer are more receptive to anti-epidermal growth factor receptor therapies, like Erbitux, according to a statement.

The assay consists of a 34-mutation panel based on beads, emulsion, amplification and magnetics technology, and only requires a 10 ml blood sample. — Anisa Jibrell